PE20030744A1 - Transdiferenciacion de celulas acinosas pancreaticas - Google Patents

Transdiferenciacion de celulas acinosas pancreaticas

Info

Publication number
PE20030744A1
PE20030744A1 PE2003000035A PE2003000035A PE20030744A1 PE 20030744 A1 PE20030744 A1 PE 20030744A1 PE 2003000035 A PE2003000035 A PE 2003000035A PE 2003000035 A PE2003000035 A PE 2003000035A PE 20030744 A1 PE20030744 A1 PE 20030744A1
Authority
PE
Peru
Prior art keywords
cells
mammal
beta cells
acine
transdifferentiation
Prior art date
Application number
PE2003000035A
Other languages
English (en)
Inventor
Lawrence Rosenberg
Original Assignee
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mcgill filed Critical Univ Mcgill
Publication of PE20030744A1 publication Critical patent/PE20030744A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN METODO PARA INDUCIR LA PRODUCCION DE CELULAS BETA EN UN MAMIFERO QUE COMPRENDE ADMINISTRAR LOCALMENTE MICROESFERAS DE UNA CANTIDAD EFECTIVA DEL PENTADECAPEPTIDO INGAP, O UNA PORCION ACTIVA EL MISMO, A CELULAS ACINOSAS DE UN MAMIFERO LAS QUE SE TRASDIFERENCIAN Y ADQUIEREN LAS CARACTERISTICAS DE CELULAS BETA Y PRODUCEN INSULINA. EL INGAP ES UNA PROTEINA CELULAR ACINOSA Y ACTUA PARA ESTIMULAR LAS CELULAS DUCTALES PARA DIFERENCIARLAS, PARA LLEGAR A SER CELULAS BETA LAS QUE PUEDEN SER USADAS INTER ALIA PARA TRASPLANTE Y MEJORAR EL ESTADO GLICEMICO DEL MAMIFERO
PE2003000035A 2002-01-11 2003-01-09 Transdiferenciacion de celulas acinosas pancreaticas PE20030744A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34689002P 2002-01-11 2002-01-11

Publications (1)

Publication Number Publication Date
PE20030744A1 true PE20030744A1 (es) 2003-10-24

Family

ID=23361448

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000035A PE20030744A1 (es) 2002-01-11 2003-01-09 Transdiferenciacion de celulas acinosas pancreaticas

Country Status (20)

Country Link
US (1) US7662768B2 (es)
EP (1) EP1463801B1 (es)
JP (1) JP2005514426A (es)
KR (1) KR20040072680A (es)
CN (1) CN1610693A (es)
AR (1) AR038281A1 (es)
AT (1) ATE404661T1 (es)
AU (1) AU2003201553A1 (es)
BR (1) BR0306656A (es)
CA (1) CA2469052A1 (es)
DE (1) DE60322831D1 (es)
IL (1) IL162749A0 (es)
MA (1) MA27413A1 (es)
MX (1) MXPA04006385A (es)
NO (1) NO20042205L (es)
PE (1) PE20030744A1 (es)
PL (1) PL371260A1 (es)
RU (1) RU2004119417A (es)
TW (1) TW200302228A (es)
WO (1) WO2003057862A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003275853A1 (en) * 2002-10-24 2004-05-13 Mcgill University Use of ingap for reversing diabetes
US20160039877A1 (en) 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815129B1 (en) * 1995-02-22 2011-01-05 Eastern Virginia Medical School of the Medical College of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
US5834590A (en) * 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
CA2463914A1 (en) * 2001-10-18 2003-04-24 Ixion Biotechnology, Inc. Conversion of liver stem and progenitor cells to pancreatic functional cells

Also Published As

Publication number Publication date
BR0306656A (pt) 2004-10-05
KR20040072680A (ko) 2004-08-18
CN1610693A (zh) 2005-04-27
US20030203850A1 (en) 2003-10-30
AU2003201553A1 (en) 2003-07-24
ATE404661T1 (de) 2008-08-15
AR038281A1 (es) 2005-01-12
NO20042205L (no) 2004-09-13
DE60322831D1 (de) 2008-09-25
EP1463801A2 (en) 2004-10-06
TW200302228A (en) 2003-08-01
MA27413A1 (fr) 2005-07-01
PL371260A1 (en) 2005-06-13
US7662768B2 (en) 2010-02-16
JP2005514426A (ja) 2005-05-19
WO2003057862A2 (en) 2003-07-17
RU2004119417A (ru) 2005-02-27
IL162749A0 (en) 2005-11-20
CA2469052A1 (en) 2003-07-17
EP1463801B1 (en) 2008-08-13
MXPA04006385A (es) 2004-10-04
WO2003057862A3 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
AR051446A1 (es) Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
SE0201996D0 (sv) Företrädesvis helt i keram utförd distans med adapter
ES2298334T3 (es) Composicion colorante para cabello que comprende arcilla.
PA8525201A1 (es) Tetrazolil-fenil acetamidas como activadores de la glucoquinasa
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
ATE215605T1 (de) In langzeitkultur gehaltene hormon-absondernde pankreatische zellen
AR022734A1 (es) Reovirus para el tratamiento de trastornos de proliferacion celular
ECSP014054A (es) Activadores de glucoquinasa alquinil fenil heteroaromatica
CY1112621T1 (el) Clostridia νευροτοξινης για χρηση στη θεραπεια της ρινικης συμφορησης
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
AR043326A1 (es) Metodos y sistemas para producir un objeto a traves de una fabricacion de formas libres solidas
JP2005503759A5 (es)
DK1349856T3 (da) Isoindolin-1-on-glucokinase-aktivatorer
NI200800175A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de abuso y adicción de sustancias.
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
UY27940A1 (es) Formulacion de anticuerpos humanos para el tratamiento de trastornos asociados con tnf-a
AR063149A1 (es) Formulaciones a base de polipeptidos estables
AR052545A1 (es) Suspension no acuosa inyectable
AR057158A1 (es) Metodo de administracion de celulas a la piel
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
BRPI0604536A (pt) terminal móvel e método para mudar o modo do mesmo
AR046210A1 (es) Preparacion solida
AR021946A1 (es) Composiciones que contienen feniramina y metodo para el tratamiento de las respuestas alergicas
PE20230091A1 (es) Conjugados terapeuticos
SV2004001674A (es) Conjugacion y proceso para la preparacion de una hormona monopegilatada terminalmente-n para una hormona para el crecimiento humano ref. 01449/1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal